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Early 
Masseter Spasm 
Generalized Muscular Rigidity 
Tachycardia 
Hypercapnia 
Hypoxia 
Combined Metabolic-Respiratory 
Acidosis 
 
Late 
Hyperthermia 
Rhabdomyolysis 
Acute Renal Failure 
Cardiac Arrhythmia 
Hypotension 
Circulatory Failure 
 
(Schneiderbanger, Johannsen, Roewer, 
& Schuster, 2014) 
 
Though hyperthermia is in the name of 
the condition, it is itself often a late 
sign and is reflective of the metabolic 
breakdown in the patient.  Thus, it is 
necessary to watch for all early signs, 
though occasionally the increase in 
temperature is the only outward sign.  
(Schuster, Johannsen, Schneiderbanger, 
& Roewer, 2013). 
 
Malignant hyperthermia, 
according to the Orphanet 
Journal of Rare Diseases, is 
“pharmacogenetic disorder of 
skeletal muscle that presents as a 
hypermetabolic response to 
potent volatile anesthetic gases” 
(Rosenberg, Pollock, Shiemann, 
Bulger, and Stowell, 2015, p. 1).  
Its incidence in anesthetics is 1 
in 10,000 to 1 in 250,000, and 
the prevalence is increased in an 
individual with certain genetic 
abnormalities that may be as 
common as one in every 400 
people.  It is caused by the 
uncontrolled rise in myoplasmic 
calcium, leading to a cascade of 
muscle activation.  The 
symptoms of malignant 
hyperthermia include 
hyperthermia, tachypnea, 
tachycardia, increased oxygen 
consumption and carbon dioxide 
production, acidosis, 
hyperkalemia, muscle rigidity, 
and rhabdomyolysis.  It is a 
condition that is likely to be fatal 
if untreated (Rosenberg et al., 
2015).  The specific treatment 
for this condition is the 
antagonist dantrolene sodium, 
which must be readily available 
whenever general anesthesia is 
utilized (Eagle Pharmaceuticals, 
2016).   
 
As the chief purpose of the 
certified registered nurse 
anesthetist is to administer safe 
and effective anesthesia to 
patients of many backgrounds 
and circumstances, intimate 
knowledge and preparation for 
malignant hyperthermia is of 
paramount import to me and my 
chosen career.  I chose this topic 
because it is one that I had only 
passing knowledge of.  Detailed 
investigation into the etiology 
and pathophysiology of the 
condition, the early warning 
signs and different 
manifestations, and identification 
of effective steps for treatment 
and crisis management are all 
important areas of discovery for 
the CRNA.  It is for this reason 
that malignant hyperthermia is a 
warranted and prudent topic of 
study. 
Malignant hyperthermia is a 
pharmacogenetic disorder which results in 
a hypermetabolic state. The signs and 
symptoms of MH are related to an 
uncontrolled release of intracellular 
calcium from skeletal muscle sarcoplasmic 
reticulum.  It occurs as a result of a 
reaction to inhaled anesthetics or the 
skeletal muscle relaxant succinylcholine in 
susceptible people.  It is an autosomal 
dominant inherited disorder, and thus a 
child of a susceptible patient has a 50% 
chance of inheriting a defective gene 
(Mitchell-Brown, 2012). A susceptible 
individual will possess a defective or 
disordered calcium channel in their 
sarcoplasmic reticulum termed the 
ryanodine receptor (RyR1).  As many as 
70% of families susceptible to MH possess 
one of the 34 causal mutations for the 
disorder (Rosenberg, Pollock, Schiemann, 
Bulger, & Stowell, 2015). The increase in 
intracellular calcium results in the muscles 
metabolizing, contracting, and causing a 
subsequent increase in oxygen 
consumption and carbon dioxide 
production, as well as ATP hydrolysis and 
heat production. 
 
During the excitation-contraction 
coupling, acetylcholine causes an action 
potential at the neuromuscular endplate.  
This action potential is then propagated to 
the transverse tubule, causing a 
displacement of the charge at the 
dihydropyridine receptor.  This voltage-
gated receptor directly transmits to the 
RyR1, opening the channel and leading to 
the large influx of calcium into the cytosol.  
This calcium presence causes the muscle 
contraction by initiation of cross-linking 
myofilaments.  Normally, active reuptake 
of the calcium would stop the muscle 
contraction, however in an MH crisis, the 
defective receptor stays open.  This 
constant activation of aerobic and 
anaerobic metabolism leads to the increase 
in oxygen consumption, hypoxia, lactate 
acidosis, excessive CO2 production, and 
increase in bodily temperature.  
Eventually, as the cellular ATP is depleted, 
the membrane integrity of the muscle cells 
will break down and rhabdomyolysis will 
occur from the potassium, creatine 
phosphokinase, and myoglobin that are 
released from the cells (Schneiderbanger, 
et al., 2014). 
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Malignant hyperthermia is rare and life threatening.  Early recognition, diagnosis, and 
treatment with dantrolene sodium have reduced the mortality rate from MH from 80% in 
the 1970s to less than 5% by 2006 (Rosenberg, et al., 2015).  Many clinicians may be 
unprepared for a crisis, failing to acknowledge the early signs and symptoms of the 
condition until it has progressed to a dangerous level. The prognosis for a patient 
suffering from a MH crisis is based on how soon MH is suspected and how quickly the 
appropriate treatments are performed.   
• Stop the trigger agent immediately 
• Continue anesthesia using intravenous opioids, sedatives, or nondepolarizing 
muscle relaxants if necessary 
• Initiate Malignant Hyperthermia Response Team 
• Give Dantrolene 2.5mg/kg and repeat as needed every 5 minutes until cardiac 
and respiratory stabilization 
• Removal of the vaporizer used for volatile anesthesia administration 
• Hyperventilation of the patient with 100% oxygen at maximum fresh gas flow 
• Increasing minute volume by approximately 2-3 times, aiming for end-tidal pCO2 
within normal limits  
• Cool patient if core temperature greater than 39˚C using cold infusions or ice 
packs in the axilla or groin 
 
(Schneiderbanger, et al., 2014), (Eagle Pharmaceuticals, 2016). 
Inhalation Anesthetic Agents: 
• Desflurane 
• Enflurane 
• Halothane 
• Isoflurane 
• Methoxyflurane 
• Sevoflurane 
• Ether 
 
Depolarizing Muscle Relaxant: 
• Succinylcholine 
 
(Schuster, et al., 2014) 
Known Drug 
Triggers: 
Given the gravity of the condition and its potential for devastating consequences, a 
prudent nurse or CRNA will do well to be mindful of the drugs that can cause the crisis, 
the early warning signs of a reaction, and the correct steps for treatment to ensure rapid, 
effective intervention.  Knowing a patient’s preoperative condition, be it through familial 
history or through genetic testing, can allow a practitioner to be ready for all eventualities 
during a case.  To improve skills, identification, and proper reactions, literature suggests 
the validity of simulation and team-based practice drills.  These exercises, ideally 
performed at least once per year, will keep staff updated, alert, and improve collaboration.  
This education is potentially life-saving.  Knowing protocols, guidelines, and how to 
prepare and administer dantrolene sodium are of chief importance.  Nurses are also 
responsible for the education of their patients.  When a patient who has had MH is to be 
discharged, it is imperative to teach these individuals so that their children and siblings 
realize their susceptibility, as well.  This knowledge could potentially save a life in the 
future (Theofanis, 2015).  The American Association of Nurse Anesthetists, in their crisis, 
preparedness, and treatment publication (2015), suggest all anesthesia professionals 
delivering MH trigger agents have all requisite drugs, supplies, and emergency equipment 
readily available.  This includes stocking dantrolene sodium at all ambulatory surgical 
centers and offices.  Effective drills for the management of MH include the following: 
• Visual aids to illustrate dantrolene preparation and administration 
• Cognitive aids and written Instructions for management/treatment steps 
• “Reader” who is responsible to read the cognitive aids aloud, which is shown to help 
with all actions being performed properly 
• Checklists, shown to  result in six-fold reduction in failure to perform all critical 
steps 
• Rotation of personnel responsibilities for MH cart helps to familiarize all team 
members with cart contents and identify out of date or out of stock items 
• Use of emergency whiteboard for designating team assignments illustrates clear 
roles 
• MH Hotline Contact Information: 1-800-644-9737 (1-800-MH-HYPER) 
(Cain, Reiss, Gettrust, & Novalija, 2014). 
Underlying  
Pathophysiology 
(Schneiderbanger, et al., 2014) 
 
Significance of Pathophysiology 
Following these steps, it may be necessary to utilize volume resuscitation, 
vasopressor administration for hemodynamic instability, blood gas analysis and lab 
draws, treatment of acidosis, or administration of beta blockers or amiodarone for 
arrhythmia.  
 
Identification for at-risk patients is of key import, as one can suspect a reaction 
from the start.  The definitive standard for diagnosis is an in vitro contracture test 
(IVCT), which is based on contracture of muscle fibers in the presence of halothane or 
caffeine.  This method has more than 
97% specificity, though it is expensive, 
only available at certain testing 
centers, requires a surgical procedure 
to obtain the tissue sample, and has 
the possibility of yielding a false 
positive or negative result.  
Alternatively, susceptibility can also be 
tested by DNA analysis.  50-70% of 
susceptibility is linked to the defective 
RyR1 with over 400 variants noted to 
have MH association (Rosenberg, et al., 
2015). 
 
Conclusion 
Malignant hyperthermia is a rare, 
life-threatening, autosomal-dominant 
inherited disorder that may lead to a 
metabolic crisis of skeletal muscle in 
susceptible individuals following 
exposure to triggering agents, such as 
volatile anesthetics or depolarizing 
muscle relaxants.  Functionally altered 
calcium release channels cause influx of 
intracellular calcium from the 
sarcoplasmic reticulum, which may lead 
rapidly to a fatal hypermetabolic state 
known as MH crisis.  Because of the 
variable clinical presentation of MH, 
ranging from only mild or moderate 
symptoms to complete MH crises, 
patient survival depends on early rec-
ognition of symptoms and prompt action 
with appropriate treatments.  In clinics 
that use known MH-triggering agents for 
induction and maintenance of general 
anesthesia, dantrolene must be available 
for immediate treatment, and those 
practitioners present must be trained in 
its use so that in the time of need the 
reaction is swift and effective 
(Schneiderbanger, et al., 2014). 
 
